Published in Cancer Weekly, March 23rd, 2004
"The objective of our study was to analyze the value of PSA levels before and after androgen suppression to predict the time to AIP in patients with advanced and metastatic prostate cancer," scientists in Spain report.
"A series of 283 prostate cancer patients under androgen suppression as a single treatment was studied. The disease was locally advanced in 98 patients and metastatic in the remaining 185," wrote J. Morote and colleagues, University of Barcelona, Hospital General Valle Hebron.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.